Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Ahmad Khan F. Abidi S, et al. Among authors: trebucq a. Eur Respir J. 2020 Mar 20;55(3):1901467. doi: 10.1183/13993003.01467-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31862767 Free article.
Should gatifloxacin be included in the model list of essential medicines?
Chiang CY, Trébucq A, Piubello A, Rieder HL, Van Deun A. Chiang CY, et al. Among authors: trebucq a. Eur Respir J. 2018 Feb 7;51(2):1702329. doi: 10.1183/13993003.02329-2017. Print 2018 Feb. Eur Respir J. 2018. PMID: 29437946 Free article. No abstract available.
Multidrug-resistant tuberculosis.
Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL. Chiang CY, et al. Among authors: trebucq a. Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7. Lancet. 2019. PMID: 31354138 No abstract available.
The looming threat of bedaquiline resistance in tuberculosis.
Chiang CY, Trébucq A, Piubello A, Rieder HL, Schwoebel V, Van Deun A. Chiang CY, et al. Among authors: trebucq a. Eur Respir J. 2020 Jun 4;55(6):2000718. doi: 10.1183/13993003.00718-2020. Print 2020 Jun. Eur Respir J. 2020. PMID: 32499309 Free article. No abstract available.
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY. Van Deun A, et al. Among authors: trebucq a. Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15. Int J Antimicrob Agents. 2020. PMID: 31626907
Numbers of tuberculosis cases: dreams and reality.
Trébucq A, Schwoebel V. Trébucq A, et al. Int J Tuberc Lung Dis. 2016 Oct;20(10):1288-1292. doi: 10.5588/ijtld.15.0873. Int J Tuberc Lung Dis. 2016. PMID: 27725036 Review.
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.
Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Cirillo DM, Koura KG, Rieder HL. Trébucq A, et al. Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17. Int J Tuberc Lung Dis. 2018. PMID: 29149917
102 results